<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:04:17Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9255971" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9255971</identifier>
        <datestamp>2022-07-06</datestamp>
        <setSpec>oncologist</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Oncologist</journal-id>
              <journal-id journal-id-type="iso-abbrev">Oncologist</journal-id>
              <journal-id journal-id-type="publisher-id">oncolo</journal-id>
              <journal-title-group>
                <journal-title>The Oncologist</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1083-7159</issn>
              <issn pub-type="epub">1549-490X</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9255971</article-id>
              <article-id pub-id-type="pmcid">PMC9255971</article-id>
              <article-id pub-id-type="pmc-uid">9255971</article-id>
              <article-id pub-id-type="pmid">35348764</article-id>
              <article-id pub-id-type="pmid">35348764</article-id>
              <article-id pub-id-type="doi">10.1093/oncolo/oyac053</article-id>
              <article-id pub-id-type="publisher-id">oyac053</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Gastrointestinal Cancer</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00010</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2246-168X</contrib-id>
                  <name>
                    <surname>Ramsdale</surname>
                    <given-names>Erika</given-names>
                  </name>
                  <aff><institution>James P. Wilmot Cancer Center, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                  <xref rid="c1" ref-type="corresp"/>
                  <xref rid="fn-0001" ref-type="author-notes"/>
                  <!--erika_ramsdale@urmc.rochester.edu-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2936-5794</contrib-id>
                  <name>
                    <surname>Mohamed</surname>
                    <given-names>Mostafa</given-names>
                  </name>
                  <aff><institution>James P. Wilmot Cancer Center, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                  <xref rid="fn-0001" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yu</surname>
                    <given-names>Veronica</given-names>
                  </name>
                  <aff><institution>James P. Wilmot Cancer Center, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Otto</surname>
                    <given-names>Ethan</given-names>
                  </name>
                  <aff><institution>James P. Wilmot Cancer Center, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Juba</surname>
                    <given-names>Katherine</given-names>
                  </name>
                  <aff><institution>Department of Pharmacy Practice, Wegmans School of Pharmacy</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>Department of Pharmacy, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Awad</surname>
                    <given-names>Hala</given-names>
                  </name>
                  <aff><institution>Clinical &amp; Translational Science Institute, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moorthi</surname>
                    <given-names>Kiran</given-names>
                  </name>
                  <aff><institution>James P. Wilmot Cancer Center, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Plumb</surname>
                    <given-names>Sandy</given-names>
                  </name>
                  <aff><institution>James P. Wilmot Cancer Center, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patil</surname>
                    <given-names>Amita</given-names>
                  </name>
                  <aff><institution>School of Nursing, Johns Hopkins University</institution>, <addr-line>Baltimore, MD</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vogelzang</surname>
                    <given-names>Nicholas</given-names>
                  </name>
                  <aff><institution>Nevada Cancer Research Foundation, NCI Community Oncology Research Program</institution>, <addr-line>Las Vegas, NV</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dib</surname>
                    <given-names>Elie</given-names>
                  </name>
                  <aff><institution>St. Joseph Mercy Cancer Center</institution>, <addr-line>Ypsilanti, MI</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mohile</surname>
                    <given-names>Supriya</given-names>
                  </name>
                  <aff><institution>James P. Wilmot Cancer Center, University of Rochester Medical Center</institution>, <addr-line>Rochester, NY</addr-line>, <country country="US">USA</country></aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="c1">Corresponding Author: Erika Ramsdale, MD, James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA. Tel: <phone>585-275-2376</phone>; Email: <email>erika_ramsdale@urmc.rochester.edu</email></corresp>
                <fn id="fn-0001">
                  <p>E.R. and M.M. contributed equally to this work.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="collection">
                <month>7</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-03-28">
                <day>28</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>28</day>
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <volume>27</volume>
              <issue>7</issue>
              <fpage>e580</fpage>
              <lpage>e588</lpage>
              <history>
                <date date-type="received">
                  <day>31</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022. Published by Oxford University Press.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="oyac053.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Purpose</title>
                  <p>Polypharmacy is prevalent in older adults starting cancer treatment and associated with potentially inappropriate medications (PIM), potential drug-drug interactions (DDI), and drug-cancer treatment interactions (DCI). For a large cohort of vulnerable older adults with advanced cancer starting treatment, we describe patterns of prescription and nonprescription medication usage, the prevalence of PIM, and the prevalence, severity, and type of DDI/DCI.</p>
                </sec>
                <sec id="s2">
                  <title>Methods</title>
                  <p>This secondary analysis used baseline data from a randomized study enrolling patients aged ≥70 years with advanced cancer starting a new systemic cancer treatment (University of Rochester Cancer Center [URCC] 13059; PI: Mohile). PIM were categorized using 2019 Beers criteria and Screening Tool of Older Persons’ Prescriptions. Potential DDI/DCI were evaluated using Lexi-Interact Online. Medication classification followed the World Health Organization Anatomical Therapeutic Chemical system. Bivariate associations were evaluated between sociodemographic and geriatric assessment (GA) measures and medication measures. Chord diagrams and network analysis were used to understand and describe DDI/DCI.</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p>Among 718 patients (mean age 77.6 years), polypharmacy (≥5 medications), excessive polypharmacy (≥10 medications), and ≥1 PIM were identified in 61.3%,14.5%, and 67.1%, respectively. Cardiovascular medications were the most prevalent (47%), and nonprescription medications accounted for 26% of total medications and 40% of PIM. One-quarter of patients had ≥1 potential major DDI not involving cancer treatment, and 5.4% had ≥1 potential major DCI. Each additional medication increased the odds of a potential major DDI and DCI by 39% and 12%, respectively. Polypharmacy and PIM are associated with multiple GA domains.</p>
                </sec>
                <sec id="s4">
                  <title>Conclusion</title>
                  <p>In a cohort of vulnerable older adults with advanced cancer starting treatment, polypharmacy, PIM, and potential DDI/DCI are very common. Nonprescription medications are frequently PIMs and/or involved in potential DDI/DCI.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser">
                <p>Polypharmacy, the concurrent usage of multiple medications, is common in older adults with cancer and is associated with adverse outcomes. This article characterizes polypharmacy, potentially inappropriate medications, and potential drug-drug interactions and drug-cancer treatment interactions in a large cohort of older adults with advanced cancer.</p>
              </abstract>
              <kwd-group>
                <kwd>polypharmacy</kwd>
                <kwd>medication use</kwd>
                <kwd>drug-drug interactions</kwd>
                <kwd>geriatric oncology</kwd>
                <kwd>potentially inappropriate medications</kwd>
                <kwd>supportive care</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIA</institution>
                      <institution-id institution-id-type="DOI">10.13039/100000049</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R21/R33AG059206</award-id>
                  <award-id>U01CA233167</award-id>
                  <award-id>R03AG067977</award-id>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>NCI</institution>
                      <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UG1CA189961</award-id>
                  <award-id>K08CA248721</award-id>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <boxed-text position="float" id="B1">
              <caption>
                <title>Implications for Practice</title>
              </caption>
              <p>Polypharmacy is prevalent in older adults with cancer. It increases the risk of potentially inappropriate medications (PIMs), potential drug-drug interactions (DDI), and potential drug-cancer therapy interactions (DCI). This study describes medication usage in a large cohort of older patients with cancer starting chemotherapy in community oncology practices, including a detailed examination and visualization of the medications most often contributing to potential DDI/DCI. Notably, nonprescription medications, not often included in other analyses, are commonly PIMs and/or contribute to potential DDI/DCI. This study yields highly pragmatic information to help focus awareness and attention on the medications which may pose risk in older patients starting cancer treatment.</p>
            </boxed-text>
            <sec id="s5">
              <title>Introduction</title>
              <p>Polypharmacy, the concurrent usage of multiple medications, is common in older adults with cancer<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> and associated with numerous adverse outcomes. Older adults are more likely than their younger counterparts to be prescribed multiple medications due to age-related multimorbidity,<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> frailty, and other geriatric syndromes.<sup><xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0004" ref-type="bibr">4</xref></sup> Fragmented care across multiple specialties<sup><xref rid="CIT0005" ref-type="bibr">5</xref></sup> and “prescribing cascades,”<sup><xref rid="CIT0006" ref-type="bibr">6</xref></sup> the prescription of additional medications to mitigate adverse effects of another medication, are also common. Polypharmacy engenders a higher risk of patients taking “potentially inappropriate medications” (PIMs),<sup><xref rid="CIT0007" ref-type="bibr">7</xref></sup> drugs which have risks higher than anticipated benefits. Polypharmacy and PIMs are associated with functional decline,<sup><xref rid="CIT0008" ref-type="bibr">8</xref></sup> falls,<sup><xref rid="CIT0009" ref-type="bibr">9</xref></sup> hospitalizations,<sup><xref rid="CIT0010" ref-type="bibr">10</xref></sup> and mortality<sup><xref rid="CIT0008" ref-type="bibr">8</xref>,<xref rid="CIT0011" ref-type="bibr">11</xref></sup> in older adults.</p>
              <p>Older adults with cancer, who are more likely to have frailty, disability, and geriatric syndromes than older patients without cancer,<sup><xref rid="CIT0012" ref-type="bibr">12</xref></sup> may be at particularly high risk of adverse events from PIMs. PIMs have been shown to decrease tolerance of cancer treatment<sup><xref rid="CIT0013" ref-type="bibr">13</xref></sup> and worsen outcomes including physical function.<sup><xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0015" ref-type="bibr">15</xref></sup> Polypharmacy and PIMs also increase the risk of clinically significant drug-drug interactions (DDI) and drug-cancer treatment interactions (DCI) in those receiving cancer treatments.<sup><xref rid="CIT0016" ref-type="bibr">16</xref></sup></p>
              <p>Polypharmacy and PIMs are understudied in older adults with cancer, and available data are heterogeneous. Estimates of polypharmacy prevalence vary widely due to inconsistent definitions.<sup><xref rid="CIT0017" ref-type="bibr">17</xref></sup> Although the most common definition for polypharmacy in the literature is ≥5 medications,<sup><xref rid="CIT0018" ref-type="bibr">18</xref></sup> cut-off values range from 3 to 10 medications.<sup><xref rid="CIT0014" ref-type="bibr">14</xref></sup> The use of ≥10 medications is often called “hyperpolypharmacy” or “excessive polypharmacy.”<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> Moreover, studies often include only scheduled prescription medications, overlooking over-the-counter (OTC) medications, complementary/alternative medications,<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> and medications taken on an as-needed basis. These omitted categories include many common PIMs in older adults (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], antihistamines, and proton pump inhibitors [PPIs]),<sup><xref rid="CIT0019" ref-type="bibr">19</xref></sup> as well as medications that increase the risk of DDIs.</p>
              <p>This study aims to characterize polypharmacy, PIMs, and potential DDI/DCI in a large cohort (<italic toggle="yes">n</italic> = 718) of vulnerable older adults with advanced cancer recruited to a national prospective cluster-randomized trial of geriatric assessment (GA), conducted in community-based (“real world”) oncology practices.<sup><xref rid="CIT0020" ref-type="bibr">20</xref></sup></p>
            </sec>
            <sec sec-type="materials" id="s6">
              <title>Methods</title>
              <sec id="s7">
                <title>Study Design</title>
                <p>This is a secondary analysis of baseline data from a nationwide, multicenter, cluster-randomized study that assessed whether providing information regarding GA to community oncologists reduced clinician-rated grade 3-5 chemotherapy toxicity in older patients with advanced cancer starting a new cancer treatment regimen (Geriatric Assessment for Patients [GAP70+] study; University of Rochester Cancer Center [URCC] 13059, PI: Mohile; ClinicalTrials.gov identifier: NCT02054741).<sup><xref rid="CIT0020" ref-type="bibr">20</xref></sup> Enrollment of participants occurred between July 2014 and March 2019. A polypharmacy log, including medication name, dose, primary indication, start and end dates, frequency, and route of administration was completed for all the participants at baseline by a clinical research associate at each study site. Recorded medication names were all converted to generic names prior to analysis, and duplicate medications (ie, if a medication was accidentally recorded twice) were eliminated. The primary study was conducted by the URCC NCI Community Oncology Research Program Research Base and approved by the Institutional Review Boards at participating sites. All participants provided written informed consent.</p>
              </sec>
              <sec id="s8">
                <title>Participants</title>
                <p>Eligible patients were (1) aged ≥70 years, (2) diagnosed with incurable stage III/IV solid tumor or lymphoma, (3) impaired in at least one GA domain excluding the polypharmacy domain, and (4) planning to start a new cancer treatment regimen with a high risk of grade 3-5 toxicity based on Common Terminology Criteria for Adverse Events, v4.<sup><xref rid="CIT0021" ref-type="bibr">21</xref></sup> Eligible regimens were determined based on enrolling physicians’ discretion and were reviewed by blinded clinical staff at the URCC Research Base.</p>
              </sec>
              <sec id="s9">
                <title>Medication Review</title>
                <p>At baseline and prior to initiation of the new cancer treatment regimen, the polypharmacy log captured regular medications (prescription, OTC, and complementary/alternative medications) received by the patient within the prior 2 weeks. Cancer therapies and supportive care medications were collected in a separate log and not included in the total medication count, PIM evaluation, or DDI/DCI analyses. Polypharmacy was defined as using ≥5 regular medications while excessive polypharmacy was defined using ≥10 regular medications.</p>
                <p>PIMs were categorized using 2 screening tools: the 2019 Beers criteria,<sup><xref rid="CIT0022" ref-type="bibr">22</xref></sup> endorsed by the American Geriatrics Society, and the Screening Tool of Older Person’s Prescriptions (STOPP) criteria,<sup><xref rid="CIT0023" ref-type="bibr">23</xref></sup> a European screening tool developed on the basis of expert consensus and evidence-based criteria. Drug interactions were reviewed using Lexi-Interact Online.<sup><xref rid="CIT0024" ref-type="bibr">24</xref></sup> Potential DDIs were categorized as any category C (monitor therapy), D (consider therapy modification), or X (avoid combination) interactions between 2 regular (non-cancer treatment) drugs. Potential major DDI are any category D or X interactions. Potential DCI is any category C, D, or X interactions between a regular drug and a cancer treatment drug (not including supportive care medications), and potential major DCI is any category D or X interactions between a regular drug and a cancer treatment drug.</p>
                <p>Medication classes were identified using the 5 nested levels of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system.<sup><xref rid="CIT0025" ref-type="bibr">25</xref></sup> In this analysis, we identified the first 3 levels of classification (first level: Anatomical or Pharmacological group; second level: Pharmacological or Therapeutic subgroup, and third level: Chemical, Pharmacological or Therapeutic subgroup). Substances not explicitly listed in the WHO ATC Index were classified by their main active ingredient and/or primary indication according to the Guidelines for ATC classification.<sup><xref rid="CIT0025" ref-type="bibr">25</xref></sup></p>
              </sec>
              <sec id="s10">
                <title>Baseline Variables</title>
                <p>Socio-demographic variables included age, gender, race (White, Black, and others), education (less than high school, high school graduate, and some college or more), marital status (never married, married/domestic partner, and separated/widowed/divorced), and income (≤$50 000 and &gt;$50 000/declined to answer). Clinical variables included cancer type (gastrointestinal, lung, others), cancer stage (stage III, stage IV), line of palliative treatment (first versus second-line or later), life expectancy estimated by the physician (≤1 year and &gt;1 year), and physician-reported Karnofsky Performance Score (KPS, 40-60, 70-80, and 90-100).<sup><xref rid="CIT0026" ref-type="bibr">26</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref></sup> GA domains were captured using validated tools with established cut-offs for impairment including comorbidity, functional status (measured by the ability to complete activities of daily living), physical performance (using objective measures), cognition, social support, psychological health, and nutritional status. These domains have been detailed previously (<xref rid="sup2" ref-type="supplementary-material">Supplementary Table 1</xref>).</p>
              </sec>
              <sec id="s11">
                <title>Data Analysis</title>
                <p>Descriptive analyses were performed to evaluate medication variables related to polypharmacy, PIM, and drug interactions. Means and SD were generated for continuous data, and proportions and frequencies for categorical data. Bivariate associations between baseline variables, polypharmacy/PIM, and potential DDI/DCI were calculated by using Fisher’s exact test and Pearson’s χ<sup>2</sup> test for categorical variables and independent <italic toggle="yes">t</italic>-test for continuous variable (total number of medications). Two-sided <italic toggle="yes">P</italic>-values of &lt;.05 were considered statistically significant. Chord diagrams were used to visualize the frequency of potential DDI and DCI between medications, at all levels of WHO ATC classification. Methods of social network analysis<sup><xref rid="CIT0028" ref-type="bibr">28</xref></sup> were used to examine and quantify the characteristics and interconnectedness of DDI and DCI “networks.” Assuming a network, where each medication or medication subgroup is a “node,” and connections between nodes represented a DDI, we measured density (existing connections as a fraction of all possible connections between nodes), diameter (the maximum shortest travel distance between any 2 nodes), and triadic closure (the percentage chance that, if 2 nodes are connected to a third node, the 2 nodes are themselves connected) for the top 3 levels of the WHO ATC classification as well as the individual medication level. Analyses were conducted with SAS 9.4 and Python 3.7.4.</p>
              </sec>
            </sec>
            <sec id="s12">
              <title>Results</title>
              <sec id="s13">
                <title>Baseline Characteristics</title>
                <p>Among 718 participants, the mean age was 77.2 years (range 70-96); 43.3% (<italic toggle="yes">n</italic> = 311) identified as female, 87.5% (<italic toggle="yes">n</italic> = 628) identified as non-Hispanic White, and 87.5% (<italic toggle="yes">n</italic> = 628) had stage IV cancer. The mean number of GA domain impairments was 4.5 (SD 1.6), 67.5% were considered impaired on the comorbidity scale (≥1 comorbidity that affected the patient a “great deal,” or ≥3 that affected the patient “somewhat” on the modified Older American Resources and Services comorbidity scale) and 57.5% (<italic toggle="yes">n</italic> = 412) were considered functionally impaired based on GA (<xref rid="T1" ref-type="table">Table 1</xref>). The most common non-cancer comorbidities were hypertension (62.0%, <italic toggle="yes">n</italic> = 445), arthritis (49.3%, <italic toggle="yes">n</italic> = 354), heart diseases (30.1%, <italic toggle="yes">n</italic> = 216), and diabetes mellitus (24.8%, <italic toggle="yes">n</italic> = 178). The average number of comorbidities per patient was 3.2 (range 0-9).</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1.</label>
                  <caption>
                    <p>Association of baseline variables and polypharmacy (≥ 5 medications).</p>
                  </caption>
                  <table frame="hsides" rules="groups" width="100%" border="1">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Variable</th>
                        <th align="left" rowspan="1" colspan="1">Category</th>
                        <th align="left" rowspan="1" colspan="1">All patients</th>
                        <th align="left" rowspan="1" colspan="1">Polypharmacy</th>
                        <th align="left" rowspan="1" colspan="1">No polypharmacy</th>
                        <th align="left" rowspan="1" colspan="1">POR</th>
                        <th align="left" colspan="2" rowspan="1">95% CI</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">N</italic>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">718 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">440 (61.3%)</td>
                        <td align="left" rowspan="1" colspan="1">278 (38.7%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" colspan="2" rowspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Age, years<xref rid="T1Fn4" ref-type="table-fn"><sup>*</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">70-74</td>
                        <td align="left" rowspan="1" colspan="1">271 (37.7%)</td>
                        <td align="left" rowspan="1" colspan="1">162 (36.8%)</td>
                        <td align="left" rowspan="1" colspan="1">109 (39.2%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">75-79</td>
                        <td align="left" rowspan="1" colspan="1">225 (31.3%)</td>
                        <td align="left" rowspan="1" colspan="1">130 (29.6%)</td>
                        <td align="left" rowspan="1" colspan="1">95 (34.2%)</td>
                        <td align="left" rowspan="1" colspan="1">0.92</td>
                        <td align="left" rowspan="1" colspan="1">0.64</td>
                        <td align="left" rowspan="1" colspan="1">1.32</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥<?fcolor_end?>80</td>
                        <td align="left" rowspan="1" colspan="1">222 (30.9%)</td>
                        <td align="left" rowspan="1" colspan="1">148 (33.6%)</td>
                        <td align="left" rowspan="1" colspan="1">74 (26.6%)</td>
                        <td align="left" rowspan="1" colspan="1">1.35</td>
                        <td align="left" rowspan="1" colspan="1">0.93</td>
                        <td align="left" rowspan="1" colspan="1">1.95</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">Gender<xref rid="T1Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">Male</td>
                        <td align="left" rowspan="1" colspan="1">405 (56.4%)</td>
                        <td align="left" rowspan="1" colspan="1">245 (55.8%)</td>
                        <td align="left" rowspan="1" colspan="1">160 (57.8%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female</td>
                        <td align="left" rowspan="1" colspan="1">311 (43.3%)</td>
                        <td align="left" rowspan="1" colspan="1">194 (44.2%)</td>
                        <td align="left" rowspan="1" colspan="1">117 (42.2%)</td>
                        <td align="left" rowspan="1" colspan="1">1.08</td>
                        <td align="left" rowspan="1" colspan="1">0.80</td>
                        <td align="left" rowspan="1" colspan="1">1.47</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Race<xref rid="T1Fn2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">White</td>
                        <td align="left" rowspan="1" colspan="1">628 (87.5%)</td>
                        <td align="left" rowspan="1" colspan="1">384 (87.67%)</td>
                        <td align="left" rowspan="1" colspan="1">244 (88.1%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Black</td>
                        <td align="left" rowspan="1" colspan="1">52 (7.2%)</td>
                        <td align="left" rowspan="1" colspan="1">30 (6.85%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (7.9%)</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                        <td align="left" rowspan="1" colspan="1">1.54</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Others</td>
                        <td align="left" rowspan="1" colspan="1">35 (4.9%)</td>
                        <td align="left" rowspan="1" colspan="1">24 (5.84%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (4.0%)</td>
                        <td align="left" rowspan="1" colspan="1">1.39</td>
                        <td align="left" rowspan="1" colspan="1">0.67</td>
                        <td align="left" rowspan="1" colspan="1">2.88</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Education<xref rid="T1Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">&lt; High school</td>
                        <td align="left" rowspan="1" colspan="1">111 (15.5%)</td>
                        <td align="left" rowspan="1" colspan="1">70 (15.95%)</td>
                        <td align="left" rowspan="1" colspan="1">41 (14.8%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">High school</td>
                        <td align="left" rowspan="1" colspan="1">244 (34.0%)</td>
                        <td align="left" rowspan="1" colspan="1">146 (33.26%)</td>
                        <td align="left" rowspan="1" colspan="1">98 (35.38%)</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                        <td align="left" rowspan="1" colspan="1">0.55</td>
                        <td align="left" rowspan="1" colspan="1">1.39</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">College or above</td>
                        <td align="left" rowspan="1" colspan="1">361 (50.3%)</td>
                        <td align="left" rowspan="1" colspan="1">223 (50.80%)</td>
                        <td align="left" rowspan="1" colspan="1">138 (49.82%)</td>
                        <td align="left" rowspan="1" colspan="1">0.95</td>
                        <td align="left" rowspan="1" colspan="1">0.61</td>
                        <td align="left" rowspan="1" colspan="1">1.47</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Income<xref rid="T1Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">≤$50 000</td>
                        <td align="left" rowspan="1" colspan="1">371 (51.7%)</td>
                        <td align="left" rowspan="1" colspan="1">235 (53.53%)</td>
                        <td align="left" rowspan="1" colspan="1">136 (49.10%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&gt;50 000</td>
                        <td align="left" rowspan="1" colspan="1">190 (26.5%)</td>
                        <td align="left" rowspan="1" colspan="1">114 (25.97%)</td>
                        <td align="left" rowspan="1" colspan="1">76 (27.44%)</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                        <td align="left" rowspan="1" colspan="1">0.61</td>
                        <td align="left" rowspan="1" colspan="1">1.24</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Declined to answer</td>
                        <td align="left" rowspan="1" colspan="1">155 (21.6%)</td>
                        <td align="left" rowspan="1" colspan="1">90 (20.50%)</td>
                        <td align="left" rowspan="1" colspan="1">65 (23.47%)</td>
                        <td align="left" rowspan="1" colspan="1">0.80</td>
                        <td align="left" rowspan="1" colspan="1">0.55</td>
                        <td align="left" rowspan="1" colspan="1">1.18</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Marital status<xref rid="T1Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">Single</td>
                        <td align="left" rowspan="1" colspan="1">17 (2.4%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (2.1%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (2.9%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Married/domestic partnership</td>
                        <td align="left" rowspan="1" colspan="1">449 (62.5%)</td>
                        <td align="left" rowspan="1" colspan="1">286 (65.2%)</td>
                        <td align="left" rowspan="1" colspan="1">63 (58.8%)</td>
                        <td align="left" rowspan="1" colspan="1">1.56</td>
                        <td align="left" rowspan="1" colspan="1">0.59</td>
                        <td align="left" rowspan="1" colspan="1">4.12</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Separated/ widowed/divorced</td>
                        <td align="left" rowspan="1" colspan="1">250 (34.8%)</td>
                        <td align="left" rowspan="1" colspan="1">144 (32.8%)</td>
                        <td align="left" rowspan="1" colspan="1">106 (38.3%</td>
                        <td align="left" rowspan="1" colspan="1">1.21</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                        <td align="left" rowspan="1" colspan="1">3.23</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="7" colspan="1">Cancer type</td>
                        <td align="left" rowspan="1" colspan="1">Gastrointestinal</td>
                        <td align="left" rowspan="1" colspan="1">246 (34.2%)</td>
                        <td align="left" rowspan="1" colspan="1">143 (32.5%)</td>
                        <td align="left" rowspan="1" colspan="1">103 (37.4%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Genitourinary</td>
                        <td align="left" rowspan="1" colspan="1">109 (15.2%)</td>
                        <td align="left" rowspan="1" colspan="1">65 (14.8%)</td>
                        <td align="left" rowspan="1" colspan="1">44 (15.8%)</td>
                        <td align="left" rowspan="1" colspan="1">1.07</td>
                        <td align="left" rowspan="1" colspan="1">0.68</td>
                        <td align="left" rowspan="1" colspan="1">1.70</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gynecological</td>
                        <td align="left" rowspan="1" colspan="1">43 (6.0%)</td>
                        <td align="left" rowspan="1" colspan="1">29 (6.6%)</td>
                        <td align="left" rowspan="1" colspan="1">14 (5.0%)</td>
                        <td align="left" rowspan="1" colspan="1">1.51</td>
                        <td align="left" rowspan="1" colspan="1">0.76</td>
                        <td align="left" rowspan="1" colspan="1">2.99</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Breast</td>
                        <td align="left" rowspan="1" colspan="1">56 (7.8%)</td>
                        <td align="left" rowspan="1" colspan="1">31 (7.1%)</td>
                        <td align="left" rowspan="1" colspan="1">25 (9%)</td>
                        <td align="left" rowspan="1" colspan="1">0.90</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                        <td align="left" rowspan="1" colspan="1">1.62</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lung</td>
                        <td align="left" rowspan="1" colspan="1">180 (25.1%)</td>
                        <td align="left" rowspan="1" colspan="1">122 (27.7%)</td>
                        <td align="left" rowspan="1" colspan="1">58 (20.9%)</td>
                        <td align="left" rowspan="1" colspan="1">1.53</td>
                        <td align="left" rowspan="1" colspan="1">1.02</td>
                        <td align="left" rowspan="1" colspan="1">2.29</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lymphoma</td>
                        <td align="left" rowspan="1" colspan="1">46 (6.4%)</td>
                        <td align="left" rowspan="1" colspan="1">28 (6.4%)</td>
                        <td align="left" rowspan="1" colspan="1">18 (6.5%)</td>
                        <td align="left" rowspan="1" colspan="1">1.13</td>
                        <td align="left" rowspan="1" colspan="1">0.59</td>
                        <td align="left" rowspan="1" colspan="1">2.15</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Others</td>
                        <td align="left" rowspan="1" colspan="1">38 (5.3%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (5%)</td>
                        <td align="left" rowspan="1" colspan="1">15 (5.4%)</td>
                        <td align="left" rowspan="1" colspan="1">1.07</td>
                        <td align="left" rowspan="1" colspan="1">0.53</td>
                        <td align="left" rowspan="1" colspan="1">2.16</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">KPS</td>
                        <td align="left" rowspan="1" colspan="1">20-60</td>
                        <td align="left" rowspan="1" colspan="1">93 (13.0%)</td>
                        <td align="left" rowspan="1" colspan="1">71 (16.2%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (7.9%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">70-80</td>
                        <td align="left" rowspan="1" colspan="1">379 (52.8%)</td>
                        <td align="left" rowspan="1" colspan="1">236 (53.8%)</td>
                        <td align="left" rowspan="1" colspan="1">143 (51.6%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.51</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.30</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.86</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">90-100</td>
                        <td align="left" rowspan="1" colspan="1">244 (33.9%)</td>
                        <td align="left" rowspan="1" colspan="1">132 (30.1%)</td>
                        <td align="left" rowspan="1" colspan="1">112 (40.4%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.37</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.21</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.63</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Life expectancy<xref rid="T1Fn3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">≤12 months</td>
                        <td align="left" rowspan="1" colspan="1">238 (33.1%)</td>
                        <td align="left" rowspan="1" colspan="1">148 (34.1%)</td>
                        <td align="left" rowspan="1" colspan="1">90 (32.5%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">&gt;12 months</td>
                        <td align="left" rowspan="1" colspan="1">473 (66.0%)</td>
                        <td align="left" rowspan="1" colspan="1">286 (65.9%)</td>
                        <td align="left" rowspan="1" colspan="1">187 (67.5%)</td>
                        <td align="left" rowspan="1" colspan="1">0.93</td>
                        <td align="left" rowspan="1" colspan="1">0.68</td>
                        <td align="left" rowspan="1" colspan="1">1.28</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1Fn1">
                      <p>Two patients had missing data.</p>
                    </fn>
                    <fn id="T1Fn2">
                      <p>Three had missing data.</p>
                    </fn>
                    <fn id="T1Fn3">
                      <p>Seven had missing data.</p>
                    </fn>
                    <fn id="T1Fn4">
                      <p><italic toggle="yes">P</italic> &lt; .05 for age as a continuous variable.</p>
                    </fn>
                    <fn id="T1Fn5">
                      <p>Abbreviations: CI, confidence interval; KPS, Karnofsky Performance Status; POR, prevalence odds ratio.</p>
                    </fn>
                    <fn id="T1Fn6">
                      <p>Bolded values are statistically significant.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s14">
                <title>Prevalence of Polypharmacy and PIMs</title>
                <p>The cohort reported 4176 occurrences of 517 distinct regular medications (prescription and nonprescription), with a median number of 5 medications per patient (range 0-24). Polypharmacy (≥5 medications) and excessive polypharmacy (≥10 medications) were identified in 61.3% (<italic toggle="yes">n</italic> = 440) and 14.5% (<italic toggle="yes">n</italic> = 104) of patients, respectively.</p>
                <p>Among prescribed medications (<italic toggle="yes">n</italic> = 3063 occurrences, 73.3% of total medications), cardiovascular agents were the most common (47.0%, <italic toggle="yes">n</italic> = 1440). Other commonly prescribed drug classes included nervous system agents such as antidepressants (13.0%, <italic toggle="yes">n</italic> = 397), alimentary tract, and metabolism medications such as antidiabetics (13.2%, <italic toggle="yes">n</italic> = 405), and systemic hormonal preparations (6.5%, <italic toggle="yes">n</italic> = 199). Lipid modifying agents (13.0%, <italic toggle="yes">n</italic> = 399), agents acting on renin-angiotensin system (9.5%, <italic toggle="yes">n</italic> = 291), beta blockers (9.5%, <italic toggle="yes">n</italic> = 291), drugs used in diabetes (7.2%, <italic toggle="yes">n</italic> = 222), and diuretics (6.6%, <italic toggle="yes">n</italic> = 201) were the most prescribed therapeutic subgroups (WHO ATC level 2 classification) (<xref rid="F1" ref-type="fig">Fig. 1</xref>). Nonprescription medications accounted for 26.7% of all medications (<italic toggle="yes">n</italic> = 1113), with vitamins (27.0%, <italic toggle="yes">n</italic> = 301), anti-anemic preparations (14.9%, <italic toggle="yes">n</italic> = 166), drugs for acid related disorders (14.6%, <italic toggle="yes">n</italic> = 162), and mineral supplements (9.8%, <italic toggle="yes">n</italic> = 110) as the most common nonprescription therapeutic subgroups (WHO ATC level 2) reported (<xref rid="F2" ref-type="fig">Fig. 2</xref>).</p>
                <fig position="float" id="F1">
                  <label>Figure 1.</label>
                  <caption>
                    <p>The most prescribed therapeutic subgroups (WHO ATC level 2 classification). </p>
                  </caption>
                  <graphic xlink:href="oyac053f0001" position="float"/>
                </fig>
                <fig position="float" id="F2">
                  <label>Figure 2.</label>
                  <caption>
                    <p>The most nonprescription therapeutic subgroups (WHO ATC level 2 classification).</p>
                  </caption>
                  <graphic xlink:href="oyac053f0002" position="float"/>
                </fig>
                <p>Based on the 2019 Beers Criteria, 447 patients (62.3%) received ≥1 PIM (range 0-8), including PPIs (22%), benzodiazepines (13%), NSAIDs (9%), and first-generation antihistamines (8%). By STOPP criteria, 206 patients (28.7%) received ≥1 PIM, including first-generation antihistamines (13%), beta-blockers (12%), benzodiazepines (9%), and NSAIDs (6%). Applying both tools, 482 patients (67.1%) received ≥1 PIM. Nonprescription medications accounted for 41.8% and 33.0% of PIM identified by Beers and STOPP criteria, respectively.</p>
              </sec>
              <sec id="s15">
                <title>Prevalence of DDI</title>
                <p>There were 1854 potential DDI identified among 490 patients. Of these, 1589 were category C affecting 64.3% of patients, 280 were category D in 22.0% of patients, and 34 were category X in 4.2% of the participants. Approximately 25% (<italic toggle="yes">n</italic> = 177) of the study participants had at least one potential major DDI not involving cancer treatment, and 5.4% (<italic toggle="yes">n</italic> = 39) had at least one potential major DCI.</p>
                <p>The most common therapeutic subgroups involved in potential DDI were drugs used in diabetes (<italic toggle="yes">n</italic> = 301 occurrences), antithrombotic agents (<italic toggle="yes">n</italic> = 202), and diuretics (<italic toggle="yes">n</italic> = 185, <xref rid="F3" ref-type="fig">Fig. 3</xref> left). The most common subgroups involved in potential major DDI were mineral supplements (<italic toggle="yes">n</italic> = 48 occurrences), lipid modifying agents (<italic toggle="yes">n</italic> = 43), and thyroid therapy (<italic toggle="yes">n</italic> = 34, <xref rid="F3" ref-type="fig">Fig. 3</xref> right). At the individual medication level, the most common agents involved in potential DDI were lisinopril (<italic toggle="yes">n</italic> = 92 occurrences), furosemide (<italic toggle="yes">n</italic> = 77), and calcium (<italic toggle="yes">n</italic> = 77, <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>).</p>
                <fig position="float" id="F3">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Chord diagrams showing most common therapeutic subgroups (WHO ATC level 2 classification) involved in all potential drug-drug interactions (left) and potential major drug-drug interactions (right). Subgroup interactions with &lt;20 (left) and &lt;3 (right) occurrences are not shown.</p>
                  </caption>
                  <graphic xlink:href="oyac053f0003" position="float"/>
                </fig>
                <p>For the medication network analysis using therapeutic subgroup level for all potential DDI, there were 40 nodes, density was 0.28 (ie, of all possible connections between subgroups, 28% signified potential DDI), diameter was 3 (ie, it took no more than 3 steps to traverse from one subgroup to any other using DDI connections), and triadic closure was 0.47 (ie, if 2 subgroups were connected to a third via a potential DDI, the 2 subgroups were also connected approximately 50% of the time). The individual medication level showed multiple disconnected sub-networks with low density and large diameters, as expected for the total number of distinct medications in the dataset (<italic toggle="yes">n</italic> = 517). No prior similar analyses exist for comparison across networks.</p>
              </sec>
              <sec id="s16">
                <title>Association of Baseline Characteristics and Polypharmacy/PIM</title>
                <p>Patients with polypharmacy (≥5 medications) were more likely to be older (mean age 77.5 vs. 76.7), have a functional impairment (62.1% vs. 50.0%), be physically impaired (94.8% vs. 90.1%), have significant comorbidity (78.0% vs. 50.7%), and have impaired psychological status (32.7% vs. 21.9%). <xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="F4" ref-type="fig">Fig. 4</xref> (left) show prevalence odds ratios (PORs) for polypharmacy by baseline characteristics. Patients who received ≥1 PIM were more likely to be younger (mean age 76.7 vs. 77.8), have physician-estimated life expectancy ≤1 year (36.9% vs. 26.5%), have a functional impairment (61.0% vs.50.0%), have significant comorbidity (74.9% vs. 52.1%); and have impaired psychological status (33.0% vs. 19.5%). <xref rid="T2" ref-type="table">Table 2</xref> and <xref rid="F4" ref-type="fig">Fig. 4</xref> (right) show PORs for PIMs by baseline characteristics.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2.</label>
                  <caption>
                    <p>Association of baseline variables and PIM (≥1 high risk medication per Beers or STOPP criteria).</p>
                  </caption>
                  <table frame="hsides" rules="groups" width="100%" border="1">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Variable</th>
                        <th align="left" rowspan="1" colspan="1">Category</th>
                        <th align="left" rowspan="1" colspan="1">All patients</th>
                        <th align="left" rowspan="1" colspan="1">PIM</th>
                        <th align="left" rowspan="1" colspan="1">No PIM</th>
                        <th align="left" rowspan="1" colspan="1">POR</th>
                        <th align="left" colspan="2" rowspan="1">95% CI</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">N</italic>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">718 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">482 (61.3%)</td>
                        <td align="left" rowspan="1" colspan="1">236 (38.7%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" colspan="2" rowspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Age, years</td>
                        <td align="left" rowspan="1" colspan="1">70-74</td>
                        <td align="left" rowspan="1" colspan="1">271 (37.7%)</td>
                        <td align="left" rowspan="1" colspan="1">190 (39.4%)</td>
                        <td align="left" rowspan="1" colspan="1">81 (34.3%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">75-79</td>
                        <td align="left" rowspan="1" colspan="1">225 (31.3%)</td>
                        <td align="left" rowspan="1" colspan="1">149 (30.9%)</td>
                        <td align="left" rowspan="1" colspan="1">76 (32.2%)</td>
                        <td align="left" rowspan="1" colspan="1">0.84</td>
                        <td align="left" rowspan="1" colspan="1">0.57</td>
                        <td align="left" rowspan="1" colspan="1">1.22</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥<?fcolor_end?>80</td>
                        <td align="left" rowspan="1" colspan="1">222 (30.9%)</td>
                        <td align="left" rowspan="1" colspan="1">143 (29.7%)</td>
                        <td align="left" rowspan="1" colspan="1">79 (33.5%)</td>
                        <td align="left" rowspan="1" colspan="1">0.77</td>
                        <td align="left" rowspan="1" colspan="1">0.53</td>
                        <td align="left" rowspan="1" colspan="1">1.13</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">Gender<xref rid="T2Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">Male</td>
                        <td align="left" rowspan="1" colspan="1">405 (56.4%)</td>
                        <td align="left" rowspan="1" colspan="1">281 (58.5%)</td>
                        <td align="left" rowspan="1" colspan="1">124 (52.5%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female</td>
                        <td align="left" rowspan="1" colspan="1">311 (43.3%)</td>
                        <td align="left" rowspan="1" colspan="1">183 (41.1%)</td>
                        <td align="left" rowspan="1" colspan="1">128 (47.2%)</td>
                        <td align="left" rowspan="1" colspan="1">0.78</td>
                        <td align="left" rowspan="1" colspan="1">0.57</td>
                        <td align="left" rowspan="1" colspan="1">1.07</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Race<xref rid="T2Fn2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">White</td>
                        <td align="left" rowspan="1" colspan="1">628 (87.5%)</td>
                        <td align="left" rowspan="1" colspan="1">427 (89.1%)</td>
                        <td align="left" rowspan="1" colspan="1">201 (85.1%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Black</td>
                        <td align="left" rowspan="1" colspan="1">52 (7.2%)</td>
                        <td align="left" rowspan="1" colspan="1">29 (6.1%)</td>
                        <td align="left" rowspan="1" colspan="1">23 (9.8%)</td>
                        <td align="left" rowspan="1" colspan="1">0.59</td>
                        <td align="left" rowspan="1" colspan="1">0.34</td>
                        <td align="left" rowspan="1" colspan="1">1.05</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Others</td>
                        <td align="left" rowspan="1" colspan="1">35 (4.9%)</td>
                        <td align="left" rowspan="1" colspan="1">23 (4.8%)</td>
                        <td align="left" rowspan="1" colspan="1">12 (5.1%)</td>
                        <td align="left" rowspan="1" colspan="1">0.90</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                        <td align="left" rowspan="1" colspan="1">1.85</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Education<xref rid="T2Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">&lt;High school</td>
                        <td align="left" rowspan="1" colspan="1">111 (15.5%)</td>
                        <td align="left" rowspan="1" colspan="1">81 (16.9%)</td>
                        <td align="left" rowspan="1" colspan="1">30 (12.7%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">High school</td>
                        <td align="left" rowspan="1" colspan="1">244 (34.0%)</td>
                        <td align="left" rowspan="1" colspan="1">169 (35.2%)</td>
                        <td align="left" rowspan="1" colspan="1">75 (31.8%)</td>
                        <td align="left" rowspan="1" colspan="1">0.84</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                        <td align="left" rowspan="1" colspan="1">1.38</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">College or above</td>
                        <td align="left" rowspan="1" colspan="1">361 (50.3%)</td>
                        <td align="left" rowspan="1" colspan="1">230 (47.9%)</td>
                        <td align="left" rowspan="1" colspan="1">131 (55.5%)</td>
                        <td align="left" rowspan="1" colspan="1">0.65</td>
                        <td align="left" rowspan="1" colspan="1">0.41</td>
                        <td align="left" rowspan="1" colspan="1">1.04</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Income<xref rid="T2Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">≤$50 000</td>
                        <td align="left" rowspan="1" colspan="1">371 (51.7%)</td>
                        <td align="left" rowspan="1" colspan="1">259 (54.0%)</td>
                        <td align="left" rowspan="1" colspan="1">112 (47.7%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">&gt;50 000</td>
                        <td align="left" rowspan="1" colspan="1">190 (26.5%)</td>
                        <td align="left" rowspan="1" colspan="1">119 (24.8%)</td>
                        <td align="left" rowspan="1" colspan="1">71 (30.1%)</td>
                        <td align="left" rowspan="1" colspan="1">0.73</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                        <td align="left" rowspan="1" colspan="1">1.05</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Declined to answer</td>
                        <td align="left" rowspan="1" colspan="1">155 (21.6%)</td>
                        <td align="left" rowspan="1" colspan="1">102 (21.3%)</td>
                        <td align="left" rowspan="1" colspan="1">53 (22.5%)</td>
                        <td align="left" rowspan="1" colspan="1">0.83</td>
                        <td align="left" rowspan="1" colspan="1">0.56</td>
                        <td align="left" rowspan="1" colspan="1">1.24</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Marital status<xref rid="T2Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">Single</td>
                        <td align="left" rowspan="1" colspan="1">17 (2.4%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (1.9%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (3.4%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Married/domestic partnership</td>
                        <td align="left" rowspan="1" colspan="1">449 (62.5%)</td>
                        <td align="left" rowspan="1" colspan="1">312 (65.0%)</td>
                        <td align="left" rowspan="1" colspan="1">137 (58.1%)</td>
                        <td align="left" rowspan="1" colspan="1">2.02</td>
                        <td align="left" rowspan="1" colspan="1">0.77</td>
                        <td align="left" rowspan="1" colspan="1">5.36</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Separated/widowed/divorced</td>
                        <td align="left" rowspan="1" colspan="1">250 (34.8%)</td>
                        <td align="left" rowspan="1" colspan="1">159 (33.1%)</td>
                        <td align="left" rowspan="1" colspan="1">91 (38.6%)</td>
                        <td align="left" rowspan="1" colspan="1">1.55</td>
                        <td align="left" rowspan="1" colspan="1">0.58</td>
                        <td align="left" rowspan="1" colspan="1">4.17</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="7" colspan="1">Cancer type</td>
                        <td align="left" rowspan="1" colspan="1">Gastrointestinal</td>
                        <td align="left" rowspan="1" colspan="1">246 (34.2%)</td>
                        <td align="left" rowspan="1" colspan="1">162 (33.9%)</td>
                        <td align="left" rowspan="1" colspan="1">84 (35.6%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Genitourinary</td>
                        <td align="left" rowspan="1" colspan="1">109 (15.2%)</td>
                        <td align="left" rowspan="1" colspan="1">65 (13.5%)</td>
                        <td align="left" rowspan="1" colspan="1">44 (18.6%)</td>
                        <td align="left" rowspan="1" colspan="1">0.74</td>
                        <td align="left" rowspan="1" colspan="1">0.41</td>
                        <td align="left" rowspan="1" colspan="1">1.34</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gynecological</td>
                        <td align="left" rowspan="1" colspan="1">43 (6.0%)</td>
                        <td align="left" rowspan="1" colspan="1">28 (5.8%)</td>
                        <td align="left" rowspan="1" colspan="1">15 (6.4%)</td>
                        <td align="left" rowspan="1" colspan="1">0.76</td>
                        <td align="left" rowspan="1" colspan="1">0.48</td>
                        <td align="left" rowspan="1" colspan="1">1.21</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Breast</td>
                        <td align="left" rowspan="1" colspan="1">56 (7.8%)</td>
                        <td align="left" rowspan="1" colspan="1">33 (6.9%)</td>
                        <td align="left" rowspan="1" colspan="1">23 (9.7%)</td>
                        <td align="left" rowspan="1" colspan="1">0.96</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                        <td align="left" rowspan="1" colspan="1">1.90</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lung</td>
                        <td align="left" rowspan="1" colspan="1">180 (25.1%)</td>
                        <td align="left" rowspan="1" colspan="1">135 (28.0%)</td>
                        <td align="left" rowspan="1" colspan="1">45 (19.1%)</td>
                        <td align="left" rowspan="1" colspan="1">1.55</td>
                        <td align="left" rowspan="1" colspan="1">1.01</td>
                        <td align="left" rowspan="1" colspan="1">2.37</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lymphoma</td>
                        <td align="left" rowspan="1" colspan="1">46 (6.4%)</td>
                        <td align="left" rowspan="1" colspan="1">34 (7.1%)</td>
                        <td align="left" rowspan="1" colspan="1">12 (5.1%)</td>
                        <td align="left" rowspan="1" colspan="1">1.46</td>
                        <td align="left" rowspan="1" colspan="1">0.72</td>
                        <td align="left" rowspan="1" colspan="1">2.97</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Others</td>
                        <td align="left" rowspan="1" colspan="1">38 (5.3%)</td>
                        <td align="left" rowspan="1" colspan="1">21 (4.5%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (6.3%)</td>
                        <td align="left" rowspan="1" colspan="1">0.95</td>
                        <td align="left" rowspan="1" colspan="1">0.46</td>
                        <td align="left" rowspan="1" colspan="1">1.96</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">KPS</td>
                        <td align="left" rowspan="1" colspan="1">20-60</td>
                        <td align="left" rowspan="1" colspan="1">93 (13.0%)</td>
                        <td align="left" rowspan="1" colspan="1">67 (13.9%)</td>
                        <td align="left" rowspan="1" colspan="1">26 (11.1%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">70-80</td>
                        <td align="left" rowspan="1" colspan="1">379 (52.8%)</td>
                        <td align="left" rowspan="1" colspan="1">271 (56.3%)</td>
                        <td align="left" rowspan="1" colspan="1">108 (46.0%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.97</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.59</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>1.61</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">90-100</td>
                        <td align="left" rowspan="1" colspan="1">244 (33.9%)</td>
                        <td align="left" rowspan="1" colspan="1">143 (29.7%)</td>
                        <td align="left" rowspan="1" colspan="1">101 (43.0%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.55</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.33</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.92</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Life expectancy<xref rid="T2Fn3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">≤12 months</td>
                        <td align="left" rowspan="1" colspan="1">238 (33.1%)</td>
                        <td align="left" rowspan="1" colspan="1">176 (36.9%)</td>
                        <td align="left" rowspan="1" colspan="1">62 (26.5%)</td>
                        <td align="left" rowspan="1" colspan="1">Ref</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">&gt;12 months</td>
                        <td align="left" rowspan="1" colspan="1">473 (66.0%)</td>
                        <td align="left" rowspan="1" colspan="1">301 (63.1%)</td>
                        <td align="left" rowspan="1" colspan="1">172 (73.5%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.62</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.44</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>0.87</bold>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T2Fn1">
                      <p>Two patients had missing data.</p>
                    </fn>
                    <fn id="T2Fn2">
                      <p>Three had missing data.</p>
                    </fn>
                    <fn id="T2Fn3">
                      <p>Seven had missing data.</p>
                    </fn>
                    <fn id="T2Fn4">
                      <p>Abbreviations: CI, confidence interval; KPS, Karnofsky Performance Status; PIM, potentially inappropriate medications; POR, prevalence odds ratio; STOPP, Screening Tool of Older Person’s Prescriptions.</p>
                    </fn>
                    <fn id="T2Fn5">
                      <p>Bolded values are statistically significant.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" id="F4">
                  <label>Figure 4.</label>
                  <caption>
                    <p>Association between impairment on geriatric assessment domains and: polypharmacy (≥5 meds, left) and PIMs (right). PIM, potentially inappropriate medications.</p>
                  </caption>
                  <graphic xlink:href="oyac053f0004" position="float"/>
                </fig>
              </sec>
              <sec id="s17">
                <title>Association of Polypharmacy/PIM Variables and Potential Drug-Drug Interaction</title>
                <p>Polypharmacy, excessive polypharmacy, and PIM were all associated with significantly increased odds of potential major DDI. There was no significant association between polypharmacy (≥5 vs. &lt;5 medications) or PIM (≥1 vs. none) and the odds of potential major DCI (<xref rid="T3" ref-type="table">Table 3</xref>). However, examining medication usage as a continuous variable, each additional medication (prescription and nonprescription) increased odds of a potential major DDI and DCI by 39% (<italic toggle="yes">P</italic> &lt; .01) and 12% (<italic toggle="yes">P</italic> &lt; .01), respectively. Each additional prescription medication increased these odds by 40% (<italic toggle="yes">P</italic> &lt; .01) and 19% (<italic toggle="yes">P</italic> &lt; .01), respectively.</p>
                <table-wrap position="float" id="T3">
                  <label>Table 3.</label>
                  <caption>
                    <p>Association of polypharmacy/PIM variables and potential drug-drug and drug-cancer treatment interactions.</p>
                  </caption>
                  <table frame="hsides" rules="groups" width="100%" border="1">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="2" colspan="1">Variable</th>
                        <th align="left" rowspan="2" colspan="1">Definition</th>
                        <th align="left" colspan="2" rowspan="1">Any potential drug-drug interactions</th>
                        <th align="left" colspan="2" rowspan="1">Any potential major drug-drug interaction</th>
                        <th align="left" colspan="2" rowspan="1">Any potential major drug-cancer treatment interaction</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">POR</th>
                        <th align="left" rowspan="1" colspan="1">95% CI</th>
                        <th align="left" rowspan="1" colspan="1">POR</th>
                        <th align="left" rowspan="1" colspan="1">95% CI</th>
                        <th align="left" rowspan="1" colspan="1">POR</th>
                        <th align="left" rowspan="1" colspan="1">95% CI</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">Polypharmacy<xref rid="T3Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">&lt; 5 meds</td>
                        <td align="left" rowspan="1" colspan="1">Ref.</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥<?fcolor_end?> 5 meds</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>19.58</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>12.78-28.71</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>5.64</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>3.55-8.95</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">1.89</td>
                        <td align="left" rowspan="1" colspan="1">0.91-3.94</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">Polypharmacy (prescription only)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;5 meds</td>
                        <td align="left" rowspan="1" colspan="1">Ref.</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥<?fcolor_end?>5 meds</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>17.11</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>10.11-28.94</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>3.21</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>2.25-4.57</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">1.49</td>
                        <td align="left" rowspan="1" colspan="1">0.78-2.85</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">Excessive Polypharmacy<xref rid="T3Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">&lt; 10 meds</td>
                        <td align="left" rowspan="1" colspan="1">Ref.</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">≥<?fcolor_end?> 10 meds</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>29.71</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>7.26-121.56</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>6.74</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>4.32-10.49</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">1.84</td>
                        <td align="left" rowspan="1" colspan="1">0.85-4.00</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PIM<xref rid="T3Fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">No</td>
                        <td align="left" rowspan="1" colspan="1">Ref.</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Yes</td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>3.19</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>2.30-4.42</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>1.58</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>1.10-2.27</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">1.23</td>
                        <td align="left" rowspan="1" colspan="1">0.62-2.43</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T3Fn1">
                      <p>Includes both prescription and nonprescription medications.</p>
                    </fn>
                    <fn id="T3Fn2">
                      <p>Abbreviations: CI, confidence interval; PIM, potentially inappropriate medications; POR, prevalence odds ratio.</p>
                    </fn>
                    <fn id="T3Fn3">
                      <p>Bolded values are statistically significant.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec id="s18">
              <title>Discussion</title>
              <p>This study details the medication usage of 718 vulnerable older adults with advanced cancer starting a cancer treatment regimen with a high risk of toxicity in the community oncology setting. Over 61% of patients had polypharmacy (≥5 medications), and nearly 15% had excessive polypharmacy (≥10 medications). In other studies of older adults with cancer, prevalence of polypharmacy ranges from 2% to 80% depending upon the specific population studied and the definition of polypharmacy.<sup><xref rid="CIT0029" ref-type="bibr">29</xref></sup> Our study also reveals 67.1% of patients taking ≥1 PIM by either Beers or STOPP criteria, which is higher than other available studies where estimates range from 19% to 52% (based only on Beers criteria in most prior studies).<sup><xref rid="CIT0029" ref-type="bibr">29</xref></sup> Polypharmacy and PIMs are markedly prevalent in this cohort, which is more likely than prior studies to be representative of older adults with advanced cancer in the community setting (where most older adults are treated).</p>
              <p>Unlike prior studies in older adults with cancer, this study reports detailed descriptive data regarding the types of medications these patients report taking regularly. Cardiovascular medications comprised nearly half of the prescribed medications reported. Interestingly, more than a quarter of the medications that patients reported taking regularly were non-prescription medications; most previous studies have only counted prescription medications, another likely reason for underestimation of PIMs. Non-prescription medications accounted for approximately 40% of PIMs detected, including common medications such as PPIs, NSAIDs, and antihistamines. Older adults may incorrectly assume that OTC medications are safe for them, and providers may be unaware of the full complement of medications their older patients are taking if a prescription was not generated. This study, therefore, helps delineate the size and shape of a problem underrecognized by both providers and patients,<sup><xref rid="CIT0030" ref-type="bibr">30</xref></sup> and highlights an opportunity for improved medication reconciliation, patient and caregiver education, deprescribing, and other interventions.<sup><xref rid="CIT0031" ref-type="bibr">31</xref></sup></p>
              <p>Patients with polypharmacy and PIMs were more likely to have a higher comorbidity burden, functional impairment (as measured by KPS and GA), and impaired psychological status (including anxiety and depression). These associations coincide with those seen in prior studies in older adults with cancer.<sup><xref rid="CIT0002" ref-type="bibr">2</xref>,<xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0029" ref-type="bibr">29</xref>,<xref rid="CIT0032" ref-type="bibr">32</xref></sup> Although this study does not provide evidence of causality, it suggests opportunities for further prospective work (for example, determining the effect of interventions for polypharmacy/PIM, like deprescribing, on physical and psychological functioning). Although patients with polypharmacy in this cohort were older on average, patients taking ≥1 PIM were younger on average and more likely to have a life expectancy of less than 1 year. A landmark study demonstrated the safety of statin discontinuation in older adults with cancer and limited life expectancy,<sup><xref rid="CIT0033" ref-type="bibr">33</xref></sup> and the OncPal deprescribing guideline was developed to assist clinicians in identifying chronic medications that may be reasonable to deprescribe in older adults with advanced cancer.<sup><xref rid="CIT0034" ref-type="bibr">34</xref></sup> Discussions around goals of care in these patients should also include conversations about medication goals. Most older patients are willing to discontinue medications after discussion with their physicians,<sup><xref rid="CIT0035" ref-type="bibr">35</xref></sup> and may derive physical and financial benefit from doing so.</p>
              <p>This study also highlighted the prevalence of potential DDI and DCI in this population. Almost 70% of patients in this cohort were at risk of DDI, and about one quarter was exposed to a potential “major” DDI, indicating that risks may outweigh the benefits of the medication combination. Nearly 5% of patients were taking medication combinations that are contraindicated, and a similar number were taking a medication that could interact with their chemotherapy regimen. These results are similar to the percentages seen in both the ELCAPA cohort of 442 patients ≥70 years starting antineoplastic therapy in France,<sup><xref rid="CIT0036" ref-type="bibr">36</xref></sup> as well as similar cohorts in the United States (<italic toggle="yes">n</italic> = 244)<sup><xref rid="CIT0016" ref-type="bibr">16</xref></sup> and Korea (<italic toggle="yes">n</italic> = 301).<sup><xref rid="CIT0037" ref-type="bibr">37</xref></sup> Considering medications interacting as analogous to a social network, the utilization of network analysis and graph theory offers a unique understanding of these data; to our knowledge, this method has not been previously reported to understand medication usage in older adults with cancer, and benchmarks do not yet exist for these types of networks. This analysis reveals that, although the network has sparse connections at the medication level (ie, only approximately 1% of the possible combinations have potential interactions), patients taking drugs from multiple therapeutic subgroups have a high risk of DDI (as 28% of therapeutic subgroup combinations result in DDI, and a high triadic closure suggests a high risk of multiple DDI within a single patient taking medications from multiple therapeutic subgroups). Older adults are more susceptible to adverse drug events (ADEs) compared to younger adults, due to polypharmacy, changes in organ function and drug metabolism, and other physiologic changes of aging. Approximately 10% of hospital admissions for older adults are associated with ADEs,<sup><xref rid="CIT0038" ref-type="bibr">38</xref>,<xref rid="CIT0039" ref-type="bibr">39</xref></sup> with most of the hospitalizations considered preventable.<sup><xref rid="CIT0040" ref-type="bibr">40</xref></sup> In older patients with cancer receiving chemotherapy, polypharmacy is associated with dramatic increases (up to 114%) in unplanned hospitalizations.<sup><xref rid="CIT0041" ref-type="bibr">41</xref>,<xref rid="CIT0042" ref-type="bibr">42</xref></sup> In the ELCAPA cohort, potential DDI (but not polypharmacy) was independently associated with the risk of unplanned hospitalization, suggesting that much of the risk may be attributable to DDI and suggesting an opportunity for further study and intervention. In our study, the risk of potential major DDI increased 39% with each additional medication (prescription or nonprescription), and the risk of an interaction with cancer treatment increased 12%, indicating a need to critically evaluate the utility and safety of every medication at the start of cancer treatment.</p>
              <p>This study has a significant limitation in that it is a secondary analysis of a randomized clinical trial that was not designed to specifically study medication usage. However, extensive information about medications was captured with high fidelity and validity, including data about nonprescription medications (which are often unreported). Compared to other studies, which are often conducted in academic centers with fit older patients, this cohort of older adults with at least one impairment other than polypharmacy may provide more representative data. This study also provides an in-depth analysis of the medications most likely to be PIMs and/or to cause DDI/DCI in this cohort, suggesting targets for further intervention and study. More work is urgently needed to implement and evaluate interventions addressing polypharmacy and PIMs in older adults with cancer, particularly those initiating cancer treatment.<sup><xref rid="CIT0043" ref-type="bibr">43</xref></sup></p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>oyac053_suppl_Supplementary_Figure</label>
                <media xlink:href="oyac053_suppl_supplementary_figure.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="sup2" position="float" content-type="local-data">
                <label>oyac053_suppl_Supplementary_Table</label>
                <media xlink:href="oyac053_suppl_supplementary_table.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <sec id="s20">
              <title>Funding</title>
              <p>The work was funded through R01 CA177592 (S.M.), K24 AG056589 (S.M.), NIA R21/R33AG059206 (S.M.), U01CA233167 (S.M.), NCI UG1CA189961 (Mustian), NCI K08CA248721 (E.R.), and NIA R03AG067977 (E.R.). All statements in this report, including its findings and conclusions, are solely those of the authors, and do not necessarily represent the official views of the funding agencies.</p>
            </sec>
            <sec id="s21">
              <title>Conflict of Interest</title>
              <p>The authors indicated no financial relationships.</p>
            </sec>
            <sec id="s22">
              <title>Author Contributions</title>
              <p><bold>Conception/Design:</bold> E.R., M.M., V.Y., E.O., K.J., K.M., S.P., A.P., S.M. <bold>Provision of study material/patients:</bold> N.V., E.D., S.M. <bold>Collection and/or assembly of data:</bold> E.R., M.M., V.Y., E.O., K.J., H.A., K.M., S.P., A.P. <bold>Data analysis and interpretation</bold>: E.R., M.M., V.Y., E.O., K.J., H.A., K.M., A.P. <bold>Manuscript writing</bold>: E.R., M.M., V.Y., E.O., K.J., H.A., K.M., S.P., A.P., N.V., E.D., S.M. <bold>Final approval of manuscript:</bold> E.R., M.M., V.Y., E.O., K.J., H.A., K.M., S.P., A.P., N.V., E.D., S.M.</p>
            </sec>
            <sec sec-type="data-availability" id="s23">
              <title>Data Availability</title>
              <p>The data underlying this article will be shared on reasonable request to the corresponding author.</p>
            </sec>
            <ref-list id="r1">
              <title>References</title>
              <ref id="CIT0001">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname><given-names>M</given-names></string-name>, <string-name><surname>Loh</surname><given-names>KP</given-names></string-name>, <string-name><surname>Nightingale</surname><given-names>G</given-names></string-name>, <string-name><surname>Mohile</surname><given-names>SG</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>HM.</given-names></string-name></person-group><article-title>Polypharmacy and potentially inappropriate medication use in geriatric oncology</article-title>. <source>J Geriatr Oncol</source>. <year>2016</year>;<volume>7</volume>(<issue>5</issue>):<fpage>346</fpage>-<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2016.07.010</pub-id><pub-id pub-id-type="pmid">27498305</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0002">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nightingale</surname><given-names>G</given-names></string-name>, <string-name><surname>Hajjar</surname><given-names>E</given-names></string-name>, <string-name><surname>Swartz</surname><given-names>K</given-names></string-name>, <string-name><surname>Andrel-Sendecki</surname><given-names>J</given-names></string-name>, <string-name><surname>Chapman</surname><given-names>A.</given-names></string-name></person-group><article-title>Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>13</issue>):<fpage>1453</fpage>-<lpage>1459</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2014.58.7550</pub-id><pub-id pub-id-type="pmid">25800766</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0003">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maggiore</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Gross</surname><given-names>CP</given-names></string-name>, <string-name><surname>Hurria</surname><given-names>A.</given-names></string-name></person-group><article-title>Polypharmacy in older adults with cancer</article-title>. <source>Oncologist</source>. <year>2010</year>;<volume>15</volume>(<issue>5</issue>):<fpage>507</fpage>-<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2009-0290</pub-id><pub-id pub-id-type="pmid">20418534</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0004">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohile</surname><given-names>SG</given-names></string-name>, <string-name><surname>Fan</surname><given-names>L</given-names></string-name>, <string-name><surname>Reeve</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of cancer with geriatric syndromes in older Medicare beneficiaries</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>11</issue>):<fpage>1458</fpage>-<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2010.31.6695</pub-id><pub-id pub-id-type="pmid">21402608</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0005">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clyne</surname><given-names>B</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>CM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>‘Potentially inappropriate or specifically appropriate?’ Qualitative evaluation of general practitioners views on prescribing, polypharmacy and potentially inappropriate prescribing in older people</article-title>. <source>BMC Fam Pract</source>. <year>2016</year>;<volume>17</volume>(<issue>1</issue>):<fpage>109</fpage>.<pub-id pub-id-type="pmid">27515854</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0006">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rochon</surname><given-names>PA</given-names></string-name>, <string-name><surname>Gurwitz</surname><given-names>JH.</given-names></string-name></person-group><article-title>The prescribing cascade revisited</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>389</volume>(<issue>10081</issue>):<fpage>1778</fpage>-<lpage>1780</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)31188-1</pub-id>.<pub-id pub-id-type="pmid">28495154</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0007">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cannon</surname><given-names>KT</given-names></string-name>, <string-name><surname>Choi</surname><given-names>MM</given-names></string-name>, <string-name><surname>Zuniga</surname><given-names>MA.</given-names></string-name></person-group><article-title>Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis</article-title>. <source>Am J Geriatr Pharmacother</source>. <year>2006</year>;<volume>4</volume>(<issue>2</issue>):<fpage>134</fpage>-<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjopharm.2006.06.010</pub-id><pub-id pub-id-type="pmid">16860260</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0008">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davies</surname><given-names>LE</given-names></string-name>, <string-name><surname>Spiers</surname><given-names>G</given-names></string-name>, <string-name><surname>Kingston</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Adverse outcomes of polypharmacy in older people: systematic review of reviews</article-title>. <source>J Am Med Dir Assoc</source>. <year>2020</year>;<volume>21</volume>(<issue>2</issue>):<fpage>181</fpage>-<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/j.jamda.2019.10.022</pub-id>.<pub-id pub-id-type="pmid">31926797</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0009">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dhalwani</surname><given-names>NN</given-names></string-name>, <string-name><surname>Fahami</surname><given-names>R</given-names></string-name>, <string-name><surname>Sathanapally</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association between polypharmacy and falls in older adults: a longitudinal study from England</article-title>. <source>BMJ Open</source>. <year>2017</year>;<volume>7</volume>(<issue>10</issue>):<fpage>e016358</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2017-016358</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0010">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jensen</surname><given-names>GL</given-names></string-name>, <string-name><surname>Friedmann</surname><given-names>JM</given-names></string-name>, <string-name><surname>Coleman</surname><given-names>CD</given-names></string-name>, <string-name><surname>Smiciklas-Wright</surname><given-names>H.</given-names></string-name></person-group><article-title>Screening for hospitalization and nutritional risks among community-dwelling older persons</article-title>. <source>Am J Clin Nutr</source>. <year>2001</year>;<volume>74</volume>(<issue>2</issue>):<fpage>201</fpage>-<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/74.2.201</pub-id><pub-id pub-id-type="pmid">11470721</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0011">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leelakanok</surname><given-names>N</given-names></string-name>, <string-name><surname>Holcombe</surname><given-names>AL</given-names></string-name>, <string-name><surname>Lund</surname><given-names>BC</given-names></string-name>, <string-name><surname>Gu</surname><given-names>X</given-names></string-name>, <string-name><surname>Schweizer</surname><given-names>ML.</given-names></string-name></person-group><article-title>Association between polypharmacy and death: a systematic review and meta-analysis</article-title>. <source>J Am Pharm Assoc</source>. <year>2017</year>;<volume>57</volume>(<issue>6</issue>):<fpage>729</fpage>-<lpage>738.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.japh.2017.06.002</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0012">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohile</surname><given-names>SG</given-names></string-name>, <string-name><surname>Xian</surname><given-names>Y</given-names></string-name>, <string-name><surname>Dale</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>(<issue>17</issue>):<fpage>1206</fpage>-<lpage>1215</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djp239</pub-id><pub-id pub-id-type="pmid">19638506</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0013">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jorgensen</surname><given-names>TL</given-names></string-name>, <string-name><surname>Herrstedt</surname><given-names>J</given-names></string-name></person-group>, <collab>Academy of Geriatric Cancer Research OUHOD</collab>. <article-title>The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer</article-title>. <source>J Geriatr Oncol</source><year>2020</year>;<volume>11</volume>(<issue>4</issue>):<fpage>593</fpage>-<lpage>602</lpage>.<pub-id pub-id-type="pmid">31883969</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0014">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohamed</surname><given-names>MR</given-names></string-name>, <string-name><surname>Ramsdale</surname><given-names>E</given-names></string-name>, <string-name><surname>Loh</surname><given-names>KP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of polypharmacy and potentially inappropriate medications with physical functional impairments in older adults with cancer</article-title>. <source>J Natl Compr Canc Netw</source>. <year>2021</year>:<fpage>1</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.6004/jnccn.2020.7628</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0015">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sarfati</surname><given-names>D</given-names></string-name>, <string-name><surname>Koczwara</surname><given-names>B</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>C.</given-names></string-name></person-group><article-title>The impact of comorbidity on cancer and its treatment</article-title>. <source>CA Cancer J Clin</source>. <year>2016</year>;<volume>66</volume>(<issue>4</issue>):<fpage>337</fpage>-<lpage>350</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21342</pub-id><pub-id pub-id-type="pmid">26891458</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0016">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Popa</surname><given-names>MA</given-names></string-name>, <string-name><surname>Wallace</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Brunello</surname><given-names>A</given-names></string-name>, <string-name><surname>Extermann</surname><given-names>M</given-names></string-name>, <string-name><surname>Balducci</surname><given-names>L.</given-names></string-name></person-group><article-title>Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy</article-title>. <source>J Geriatr Oncol</source>. <year>2014</year>;<volume>5</volume>(<issue>3</issue>):<fpage>307</fpage>-<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2014.04.002</pub-id><pub-id pub-id-type="pmid">24821377</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0017">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Masnoon</surname><given-names>N</given-names></string-name>, <string-name><surname>Shakib</surname><given-names>S</given-names></string-name>, <string-name><surname>Kalisch-Ellett</surname><given-names>L</given-names></string-name>, <string-name><surname>Caughey</surname><given-names>GE.</given-names></string-name></person-group><article-title>What is polypharmacy? A systematic review of definitions</article-title>. <source>BMC Geriatr</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>230</fpage>. <pub-id pub-id-type="doi">10.1186/s12877-017-0621-2</pub-id><pub-id pub-id-type="pmid">29017448</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0018">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turner</surname><given-names>JP</given-names></string-name>, <string-name><surname>Shakib</surname><given-names>S</given-names></string-name>, <string-name><surname>Singhal</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence and factors associated with polypharmacy in older people with cancer</article-title>. <source>Support Care Cancer</source>. <year>2014</year>;<volume>22</volume>(<issue>7</issue>):<fpage>1727</fpage>-<lpage>1734</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-014-2171-x</pub-id><pub-id pub-id-type="pmid">24584682</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0019">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vatcharavongvan</surname><given-names>P</given-names></string-name>, <string-name><surname>Puttawanchai</surname><given-names>V.</given-names></string-name></person-group><article-title>Potentially inappropriate medications among the elderly in primary care in Thailand from three different sets of criteria</article-title>. <source>Pharm Pract (Granada)</source>. <year>2019</year>;<volume>17</volume>(<issue>3</issue>):<fpage>1494</fpage>. <pub-id pub-id-type="doi">10.18549/PharmPract.2019.3.1494</pub-id><pub-id pub-id-type="pmid">31592037</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0020">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohile</surname><given-names>SG</given-names></string-name>, <string-name><surname>Mohamed</surname><given-names>MR</given-names></string-name>, <string-name><surname>Culakova</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer: a University of Rochester Cancer Center NCI community oncology research program cluster randomized clinical trial (CRCT)</article-title>. <source>J Clin Oncol</source>. <year>2020</year>;<volume>38</volume>(<issue>suppl 15</issue>):<fpage>12009</fpage>-<lpage>12009</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2020.38.15_suppl.12009</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0021">
                <label>21.</label>
                <mixed-citation publication-type="book"><collab>National Cancer Institute</collab>. <source>Common Terminology Criteria for Adverse Events (CTCAE)</source>; <year>2010</year>. Accessed <comment>June 18, 2021</comment>. <ext-link xlink:href="https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf" ext-link-type="uri">https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="CIT0022">
                <label>22.</label>
                <mixed-citation publication-type="journal"><collab>2019 AGS Beers Criteria® Update Expert Panel</collab>. <article-title>American Geriatrics Society 2019 updated AGS Beers Criteria<sup>®</sup> for potentially inappropriate medication use in older adults.</article-title><source>J Am Geriatr Soc</source>. <year>2015</year>;<volume>67</volume>(<issue>4</issue>):<fpage>674</fpage>-<lpage>694</lpage>.</mixed-citation>
              </ref>
              <ref id="CIT0023">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Mahony</surname><given-names>D</given-names></string-name>, <string-name><surname>O’Sullivan</surname><given-names>D</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>STOPP/START criteria for potentially inappropriate prescribing in older people: version 2</article-title>. <source>Age Ageing</source>. <year>2015</year>;<volume>44</volume>(<issue>2</issue>):<fpage>213</fpage>-<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1093/ageing/afu145</pub-id><pub-id pub-id-type="pmid">25324330</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0024">
                <label>24.</label>
                <mixed-citation publication-type="book"><source>Lexicomp Drug Interactions</source>. <publisher-name>Wolters Kluwer Health, Inc.</publisher-name><publisher-loc>Riverwoods, IL</publisher-loc>. Accessed <comment>June 18, 2021</comment>. <ext-link xlink:href="http://online.lexi.com" ext-link-type="uri">http://online.lexi.com</ext-link></mixed-citation>
              </ref>
              <ref id="CIT0025">
                <label>25.</label>
                <mixed-citation publication-type="book"><collab>World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology</collab>. <source>Guidelines for ATC classification and DDD Assignment</source>; <year>2022</year>. <publisher-loc>Oslo</publisher-loc>, 2021.</mixed-citation>
              </ref>
              <ref id="CIT0026">
                <label>26.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Karnofsky</surname><given-names>DA.</given-names></string-name></person-group><article-title>The clinical evaluation of chemotherapeutic agents in cancer.</article-title> In: <person-group person-group-type="editor"><string-name><surname>MacLeod</surname><given-names>CM</given-names></string-name></person-group>, ed. <source>Evaluation of Chemotherapeutic Agents. </source><publisher-name>Columbia University Press</publisher-name>; <year>1949</year>:<fpage>191</fpage>-<lpage>205</lpage>.</mixed-citation>
              </ref>
              <ref id="CIT0027">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yates</surname><given-names>JW</given-names></string-name>, <string-name><surname>Chalmer</surname><given-names>B</given-names></string-name>, <string-name><surname>McKegney</surname><given-names>FP.</given-names></string-name></person-group><article-title>Evaluation of patients with advanced cancer using the Karnofsky performance status</article-title>. <source>Cancer</source>. <year>1980</year>;<volume>45</volume>(<issue>8</issue>):<fpage>2220</fpage>-<lpage>2224</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(19800415)45:8&lt;2220::aid-cncr2820450835&gt;3.0.co;2-q</pub-id><pub-id pub-id-type="pmid">7370963</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0028">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>J.</given-names></string-name></person-group><article-title>Social network analysis</article-title>. <source>Sociology</source>. <year>1988</year>;<volume>22</volume>(<issue>1</issue>):<fpage>109</fpage>-<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1177/0038038588022001007</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0029">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohamed</surname><given-names>MR</given-names></string-name>, <string-name><surname>Ramsdale</surname><given-names>E</given-names></string-name>, <string-name><surname>Loh</surname><given-names>KP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis</article-title>. <source>Oncologist.</source><year>2020</year>;<volume>25</volume>(<issue>1</issue>):<fpage>e94</fpage>-<lpage>e108</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2019-0406</pub-id>.<pub-id pub-id-type="pmid">31570516</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0030">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sirois</surname><given-names>C</given-names></string-name>, <string-name><surname>Turner</surname><given-names>JP</given-names></string-name>, <string-name><surname>Hebert</surname><given-names>J.</given-names></string-name></person-group><article-title>Health professionals’ perspectives regarding polypharmacy in older patients with cancer: a mixed-design exploratory study</article-title>. <source>J Geriatr Oncol</source>. <year>2021</year>;<volume>12</volume>(<issue>6</issue>):<fpage>881</fpage>-<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2021.02.027</pub-id><pub-id pub-id-type="pmid">33750672</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0031">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barlow</surname><given-names>A</given-names></string-name>, <string-name><surname>Prusak</surname><given-names>ES</given-names></string-name>, <string-name><surname>Barlow</surname><given-names>B</given-names></string-name>, <string-name><surname>Nightingale</surname><given-names>G.</given-names></string-name></person-group><article-title>Interventions to reduce polypharmacy and optimize medication use in older adults with cancer</article-title>. <source>J Geriatr Oncol</source>. <year>2021</year>;<volume>12</volume>(<issue>6</issue>):<fpage>863</fpage>-<lpage>871</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2020.12.007</pub-id><pub-id pub-id-type="pmid">33353854</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0032">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Canoui-Poitrine</surname><given-names>F</given-names></string-name>, <string-name><surname>Reinald</surname><given-names>N</given-names></string-name>, <string-name><surname>Laurent</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Geriatric assessment findings independently associated with clinical depression in 1092 older patients with cancer: the ELCAPA Cohort Study</article-title>. <source>Psychooncology</source>. <year>2016</year>;<volume>25</volume>(<issue>1</issue>):<fpage>104</fpage>-<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1002/pon.3886</pub-id><pub-id pub-id-type="pmid">26123351</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0033">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kutner</surname><given-names>JS</given-names></string-name>, <string-name><surname>Blatchford</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>DH</given-names><suffix>Jr</suffix></string-name>, <etal>et al</etal></person-group>. <article-title>Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial</article-title>. <source>JAMA Intern Med</source>. <year>2015</year>;<volume>175</volume>(<issue>5</issue>):<fpage>691</fpage>-<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2015.0289</pub-id><pub-id pub-id-type="pmid">25798575</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0034">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindsay</surname><given-names>J</given-names></string-name>, <string-name><surname>Dooley</surname><given-names>M</given-names></string-name>, <string-name><surname>Martin</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline’</article-title>. <source>Support Care Cancer</source>. <year>2015</year>;<volume>23</volume>(<issue>1</issue>):<fpage>71</fpage>-<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-014-2322-0</pub-id><pub-id pub-id-type="pmid">24975044</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0035">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reeve</surname><given-names>E</given-names></string-name>, <string-name><surname>Wolff</surname><given-names>JL</given-names></string-name>, <string-name><surname>Skehan</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Assessment of attitudes toward deprescribing in older Medicare beneficiaries in the US</article-title>. <source>JAMA Intern Med</source>. <year>2018</year>;<volume>178</volume>(<issue>12</issue>):<fpage>1673</fpage>-<lpage>1680</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2018.4720</pub-id>.<pub-id pub-id-type="pmid">30326004</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0036">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beinse</surname><given-names>G</given-names></string-name>, <string-name><surname>Reitter</surname><given-names>D</given-names></string-name>, <string-name><surname>Segaux</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: a survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort</article-title>. <source>J Geriatr Oncol</source>. <year>2020</year>;<volume>11</volume>(<issue>4</issue>):<fpage>586</fpage>-<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2019.07.023</pub-id><pub-id pub-id-type="pmid">31445850</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0037">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hong</surname><given-names>S</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JH</given-names></string-name>, <string-name><surname>Chun</surname><given-names>EK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Polypharmacy, inappropriate medication use, and drug interactions in older Korean patients with cancer receiving first-line palliative chemotherapy</article-title>. <source>Oncologist</source>. <year>2020</year>;<volume>25</volume>(<issue>3</issue>):<fpage>e502</fpage>-<lpage>e511</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2019-0085</pub-id><pub-id pub-id-type="pmid">32162799</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0038">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kongkaew</surname><given-names>C</given-names></string-name>, <string-name><surname>Noyce</surname><given-names>PR</given-names></string-name>, <string-name><surname>Ashcroft</surname><given-names>DM.</given-names></string-name></person-group><article-title>Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies</article-title>. <source>Ann Pharmacother</source>. <year>2008</year>;<volume>42</volume>(<issue>7</issue>):<fpage>1017</fpage>-<lpage>1025</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1L037</pub-id><pub-id pub-id-type="pmid">18594048</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0039">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oscanoa</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Lizaraso</surname><given-names>F</given-names></string-name>, <string-name><surname>Carvajal</surname><given-names>A.</given-names></string-name></person-group><article-title>Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2017</year>;<volume>73</volume>(<issue>6</issue>):<fpage>759</fpage>-<lpage>770</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-017-2225-3</pub-id><pub-id pub-id-type="pmid">28251277</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0040">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname><given-names>M</given-names></string-name>, <string-name><surname>Nicklason</surname><given-names>F</given-names></string-name>, <string-name><surname>Vial</surname><given-names>JH.</given-names></string-name></person-group><article-title>Adverse drug events as a cause of hospital admission in the elderly</article-title>. <source>Intern Med J</source>. <year>2001</year>;<volume>31</volume>(<issue>4</issue>):<fpage>199</fpage>-<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1046/j.1445-5994.2001.00044.x</pub-id><pub-id pub-id-type="pmid">11456032</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0041">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klepin</surname><given-names>HD</given-names></string-name>, <string-name><surname>Sun</surname><given-names>CL</given-names></string-name>, <string-name><surname>Smith</surname><given-names>DD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy</article-title>. <source>JCO Oncol Pract.</source><year>2021</year>;<volume>17</volume>(<issue>6</issue>):<fpage>e740</fpage>-<lpage>e752</lpage>. <pub-id pub-id-type="doi">10.1200/OP.20.00681</pub-id><pub-id pub-id-type="pmid">33881905</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0042">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu-Yao</surname><given-names>G</given-names></string-name>, <string-name><surname>Nightingale</surname><given-names>G</given-names></string-name>, <string-name><surname>Nikita</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy</article-title>. <source>J Geriatr Oncol</source>. <year>2020</year>;<volume>11</volume>(<issue>4</issue>):<fpage>579</fpage>-<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2020.03.001</pub-id><pub-id pub-id-type="pmid">32199776</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0043">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nightingale</surname><given-names>G</given-names></string-name>, <string-name><surname>Mohamed</surname><given-names>MR</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>HM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Research priorities to address polypharmacy in older adults with cancer</article-title>. <source>J Geriatr Oncol.</source><year>2021</year>;<volume>12</volume>(<issue>6</issue>):<fpage>964</fpage>-<lpage>970</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2021.01.009</pub-id><pub-id pub-id-type="pmid">33589379</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
